Skip to content

RNA editome analysis of Parkinson's disease and its role in disease progression

RNA editome analysis of Parkinson's disease and its role in disease progression

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118224
Enrollment
Unknown
Registered
2026-02-03
Start date
2026-02-15
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson’s Disease (PD)

Interventions

Parkinson's group and non-Parkinson's group:None

Sponsors

Quzhou People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Inclusion criteria for the PD group: (1) Patients diagnosed with Parkinson’s disease (PD) according to the "Diagnostic Criteria for Parkinson’s Disease in China" issued by the Chinese Medical Association in 2016; (2) Age >= 40 years; (3) Complete clinical data and ability to cooperate with all scale assessments. 2.Control Group Inclusion Criteria: (1) Age, sex distribution, and years of education matched those of the PD group; (2) No structural abnormalities detected on routine brain MRI; (3) No history of psychiatric disorders or related medication use; (4) Normal MoCA scores.

Exclusion criteria

Exclusion criteria: 1.Exclusion criteria for the PD group: (1) secondary Parkinsonism caused by extracranial trauma, cerebrovascular disease, drugs, or tumors; (2) patients with Parkinson-plus syndromes or other neurological disorders; (3) patients with recent surgical history or major trauma; (4) patients with severe cognitive impairment, or those with other diseases that cause or potentially affect cognitive function, such as cerebellar ataxia, frontotemporal dementia, carbon monoxide poisoning, or neurosyphilis; (5) patients with incomplete clinical data or inability to cooperate in completing all required rating scales; (6) patients unable to undergo blood tests due to subjective or objective reasons. 2.Control group exclusion criteria: (1) having a first-degree relative with a neurodegenerative disease; (2) having uncontrolled severe systemic diseases (e.g., malignancy, severe cardiac, hepatic, or renal insufficiency); (3) contraindications to sample collection or inability to cooperate.

Design outcomes

Primary

MeasureTime frame
Differences in editing rates of C-to-U RNA editing sites;

Secondary

MeasureTime frame
Correlation between RNA editing metrics and disease severity;

Countries

China

Contacts

Public ContactWu An

Quzhou People's Hospital

34887740@qq.com+86 570 3125081

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026